Inositol pyrophosphates, such as diphospho-myo-inositol pentakisphosphates (InsP 7 ), are an important family of signalling molecules, implicated in many cellular processes and therapeutic indications including insulin secretion, glucose homeostasis and weight gain. To understand their cellular functions, chemical tools such as photocaged analogues for their real-time modulation in cells are required. Here we describe a concise, modular synthesis of InsP 7 and caged InsP 7 . The caged molecule is stable and releases InsP 7 only on irradiation. While photocaged InsP 7 does not enter cells, its cellular uptake is achieved using nanoparticles formed by association with a guanidinium-rich molecular transporter. This novel synthesis and unprecedented polyphosphate delivery strategy enable the first studies required to understand InsP 7 signalling in cells with controlled spatiotemporal resolution. It is shown herein that cytoplasmic photouncaging of InsP 7 leads to translocation of the PH-domain of Akt, an important signalling-node kinase involved in glucose homeostasis, from the membrane into the cytoplasm.
D iphospho-inositol polyphosphates (InsP 7 ) are second messengers involved in essential cell signalling pathways [1] [2] [3] [4] . A distinct difference of InsP 7 compared with other inositol polyphosphates is the presence of a phosphoanhydride bond in, for example, the 5-position (5-InsP 7 , Fig. 1 ), rendering them a structurally unique class of second messengers. This special feature is also the reason for their nickname 'inositol pyrophosphates'. InsP 7 are implicated in the regulation of diverse cellular and metabolic functions in different kingdoms of life [1] [2] [3] [4] [5] [6] [7] [8] . It has been proposed that InsP 7 bind to the pleckstrin homology (PH) domain of protein kinase B (Akt), and competitively suppress its specific phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ) association at the plasma membrane, thereby inhibiting phosphoinositide-dependent kinase 1 (PDK1)-mediated phosphorylation of Akt 9, 10 . However, there remains uncertainty as to whether the reduced phosphorylation of Akt is a result of the inhibition of its membrane association via its PH-domain, since the in vitro assays that have been performed do not contain any membrane or membrane mimics. In addition, InsP 7 might act either as allosteric inhibitors or as non-enzymatic phosphorylating agents or both 3, 11 . Notwithstanding, inhibition of the Akt pathway by InsP 7 has an impact on glucose uptake and insulin sensitivity, as exemplified by a mouse model that lacks inositol hexakisphosphate-kinase 1 (IP6K1). These knockout mice have reduced levels of InsP 7 and show a lean phenotype on high-fat diet concomitant with increased insulin sensitivity 9 . As a consequence, IP6K1 has recently been proposed as a novel target in the treatment of diabetes and obesity 12 . To address fundamental questions about the mechanism of action of these potent signalling molecules and their subcellular localization, the development of new chemical tools is required.
To understand cellular signalling mediated by second messengers, photocaged analogues that can be activated on demand inside living cells with spatiotemporal resolution have attracted great interest 13 . Unfortunately, preparation of such analogues often requires lengthy synthetic sequences. Phosphorylated second messengers derived from myo-inositol such as myo-inositol 1,4,5-trisphosphate ( Fig. 1 ) present additional challenges as their polyanionic nature precludes efficient cellular uptake 14 . For example, while cell-permeable and photocaged analogues of different myo-inositol polyphosphates (InsP x ) and phosphatidyl myo-inositol polyphosphates (PtdIns-P x ) have been reported [15] [16] [17] [18] , the phosphate groups typically need to be reversibly masked. This complicates their use, as multiple intracellular hydrolysis events must occur before the free polyphosphate is formed 19 . Even so, no such photocaged derivatives are currently available for the more complex diphospho-myo-inositol pentakisphosphates as, for example, 5-InsP 7 (Fig. 1) 20 .
Here we report the design, step-economical synthesis, photophysical and metabolic evaluation of photocaged 5-InsP 7, and significantly, a general solution to the delivery of unmodified polyphosphate probes into cells using guanidinium-rich molecular transporters 21 . On cytoplasmic uncaging, 5-InsP 7 -mediated PH-domain translocation from the membrane into the cytosol in living cells is demonstrated for the first time on a 15-min timescale.
Results

Synthesis.
All current synthetic approaches to access any InsP 7 isomer rely on a global hydrogenation in the last step, during which up to 13 protecting groups need to be removed [22] [23] [24] [25] [26] [27] [28] [29] [30] . Significantly, however, hydrogenation is incompatible with photocaging groups and many other functional moieties like, for example, fluorophores. To address this problem, a novel strategy based on the development of a levulinate benzyl ester adaptor (LevB) is described. The introduction of this new protecting group and its combination with fluorenylmethyl (Fm) protection [31] [32] [33] and photocage introduction enables the previously inaccessible synthesis of the first photoactivatable diphospho-inositol InsP 7 probe 9 equipped with a [7-(diethylamino)-coumarin-4-yl]methyl (DEACM) photocage (Fig. 2a) . It is noteworthy that this strategy potentially facilitates the introduction of other tags, such as, for example, photoaffinity labels and fluorophores.
The synthesis commenced with benzylidene protected 2 prepared as previously described (Fig. 2a) 23 . The 5-OH position of 2 is available for phosphitylation, allowing virtually any protected phosphate to be introduced. However, none of the existing protecting groups are compatible with the subsequent introduction of the coumarin cage. Such protecting groups would need to be stable under acidic and basic conditions and must enable double deprotection under very mild conditions. To meet these stringent requirements, a new phosphate-protecting group is required. The approach described herein is based on an Umpolung strategy that had been exploited in prodrug design for nucleotides 34, 35 . Conceptually, this strategy is useful to generally couple phenol or alcohol protecting groups to phosphates via a benzyl adaptor, greatly enhancing the available protecting group strategies for phosphates (Fig. 2b) . A novel P-amidite 3 was developed (Fig. 2, Supplementary Fig. 1 ), which is connected via a benzyl ester to a levulinate group (LevB). After oxidation to the phosphate triester 6, the LevB group can be cleaved by hydrazone formation, initiating cyclization and finally a Grob-type fragmentation to give the unprotected phosphates (Fig. 2b) .
After coupling P-amidite 3 to alcohol 2 and oxidation, all inositol-protecting groups were cleaved with TFA. The resultant protected monophosphate 4 was phosphitylated with (Fm) 2 -Pamidite 5 and oxidized. Notwithstanding the significant molecular crowding of hexakisphosphate 6, both LevB groups were efficiently cleaved under mild conditions (hydrazine*AcOH/ TFA), releasing phosphate 7. Next, the P-anhydride was formed using Fm-protected photocaged P-amidite 8 (ref. 33 ). All 11 Fm-protecting groups were then cleaved with piperidine resulting in highly pure photocaged 5-InsP 7 9 in 45% yield over 2 steps (11% overall yield from 1) on precipitation of the compound as the dodeca-piperidinium salt. The piperidinium ions can also be exchanged with sodium ions by precipitation. In addition, natural 5-InsP 7 10 can be prepared following the same strategy by using (Fm) 2 -P-amidite 5 in the anhydride forming reaction (8% overall yield from 1) 36, 37 . This eight-step synthesis represents a general strategy to access 5-InsP 7 10 and caged analogues in scalable amounts (30 mg of 9 have been prepared) and very high quality without the need for a final hydrogenation under aqueous conditions.
In vitro stability and photophysical properties. To serve as a useful tool, DEACM 5-InsP 7 9 must be stable towards enzymatic digestion to enable cellular uptake and release only on photolysis. To test its stability, 9 was incubated in tissue homogenate (brain, Fig. 3a ; liver, Supplementary Fig. 3 and Supplementary Methods) and cell extract (Supplementary Figs 4-5 and Supplementary Methods). Readout was achieved by resolution on polyacrylamide gels (35%, Fig. 3 and Supplementary Methods) 38 . DEACM 5-InsP 7 9 did not decompose under these conditions over incubation times up to 5 h (Fig. 3a , Lanes III-V and Supplementary . Thus, 9 is a probe that has the potential to be broadly applied in different cell and tissue types. Importantly, on exposure to ultraviolet light (366 nm, 4 W, distance 10 cm) in extracts, it was cleanly converted into 5-InsP 7 10, as verified by PAGE (Fig. 3a , Lanes VI and VII and Supplementary Figs 3-4) and HPLC analysis (Supplementary Fig. 6 ) with 10 as a standard.
Next, the photophysical properties of DEACM 5-InsP 7 9 were characterized. The quantum yield for the disappearance of 9 Dj chem is 0.71% at 355 nm as determined by actinometry following a novel protocol (Supplementary Methods) [39] [40] [41] . The fluorescence quantum yield j f is 6.2% and the lifetime t f is 1.2 ns. Notably, 9 also exhibits typical coumarin fluorescence at 500 nm (excitation at 386 nm; Supplementary Figs 7-10 and Supplementary Methods) 33, 42 .
Cellular delivery and uncaging. Notwithstanding the efficiency of this synthesis, it was found as expected that DEACM 5-InsP 7 9, like other polyanions 11, 14 , does not readily cross the non-polar membrane of a cell (Fig. 4b,c) . To address this problem, its non-covalent complexation, cell uptake and release using guanidinium-rich molecular transporters were studied 43 . 9 was mixed with amphipathic, guanidinium-rich transporter 11 ( Fig. 4a) , in an equimolar ratio to form nanoparticles. HeLa cells were treated with these complexes and analysed for coumarin fluorescence by flow cytometry. Significantly, while DEACM 5-InsP 7 9 itself does not appreciably enter cells, the transporter-complexed 9 does, as demonstrated by a 10-fold increase in intracellular fluorescence (Fig. 4b ). According to flow cytometry analysis, over 99% of cells display increased levels of 9 following treatment with the transporter/DEACM-InsP 7 complex (Fig. 4c) . It is important to note that other transfection reagents like Lipofectamine 2000 do not efficiently deliver 9 into cells (Fig. 4b) . (1) DCI then tBuOOH (2) 5% TFA/DCM 62±10% (two steps) Delivery and intracellular distribution of 9 were further analysed in HeLa cells by confocal microscopy after 4 and 16 h (Fig. 5) . The z-stack analysis shows DEACM 5-InsP 7 9 distributed throughout the cytoplasm at both time points (Fig. 5 , single z-slice shown). Both diffuse fluorescence and fluorescent puncta are observed, consistent with mixed diffusion or endosomal uptake and release [44] [45] [46] . This is additionally supported by a 65% reduction in cellular uptake when cells were treated at 4°C, a condition known to inhibit most endocytotic processes ( Supplementary Fig. 11 ).
Cellular uptake, stability and efficient uncaging in living cells was additionally verified by extraction of diphospho-inositol polyphosphates and other cellular phosphates based on a recently published TiO 2 microsphere enrichment method 47 . Here it is shown that this method can also be used to extract analogues such as 9 from complex cell and tissue lysates ( Fig. 3b and Supplementary Methods) enabling studies concerning its intracellular fate after delivery. After incubation of DEACM 5-InsP 7 9 with HeLa cells in the presence or absence of MoTr 11 and repeated washings to remove external 9, the extracts prepared from those cells (1 million cells) clearly showed a distinct novel band corresponding to 9 in the PAGE analysis after enrichment with TiO 2 and elution (Fig. 3b, lanes VI-VII) , whereas no such uptake could be detected in the control experiment without transporter (Fig. 3b, lane V) . To verify its identity, the band corresponding to DEACM 5-InsP 7 9 was extracted from the gel and analysed by MALDI mass spectrometry, demonstrating its intracellular stability ( Supplementary Fig. 12 and Supplementary Methods) for multiple hours. Moreover, efficient intracellular uncaging by irradiation at 366 nm was proven using the same extraction and resolution method (TiO 2 enrichment, then PAGE) in combination with mass spectrometry after extraction of Lane VIII (Fig. 3b) . These conditions were found to be of no immediate toxicity ( Supplementary Fig. 13 and Supplementary Methods). In summary, the photocaged molecule 9 is efficiently taken up by cells in the presence of MoTr 11, evenly distributed throughout the cytoplasm, stable for multiple hours in its caged form and can be selectively uncaged to 5-InsP 7 10, thus fulfilling the stringent requirements imposed on an intracellular signalling probe.
PH-domain translocation. To determine the suitability of the combined delivery and uncaging strategy for a deeper understanding of the effect of InsP 7 fluctuations, PH-domain translocation on cytoplasmic InsP 7 release was studied. The rationale for this experiment is provided by the lean phenotype displayed by IP6K1 knockout mice on high-fat diet and the observation that 48, 49 . Cells were serum-starved to induce cytoplasmic localization of the PH-domain due to absence of growth factors and therefore inactivation of the PI3K/Akt/mTOR pathway 50 . PH-eGFP plasma membrane association was then efficiently induced within 10 min on external addition of a combination of growth factors (insulin-like growth factor (IGF); endothelial growth factor (EGF)) into the medium. During the starvation period, cells were loaded with caged InsP 7 9/MoTr 11 nanoparticles for 4 h. This treatment alone had no effect on PH-domain localization. Next, cells were irradiated under a confocal laser-scanning microscope with short laser pulses (375 nm, 10 MHz, 30 s) in different areas (Fig. 6 dotted circle, and Supplementary Figs 14-23) , and PH-domain localization was traced using the green channel. After photouncaging, a delayed but complete PH-domain translocation from the plasma membrane into the cytoplasm was observed, and these results were repeated several times (n ¼ 4). Significantly, translocation did not occur when cells were incubated with photocaged InsP 7 9 or MoTr 11 only (Supplementary Figs 18-23 ). In these cases, the PH-domains remained localized on the membrane for several hours, demonstrating the need for the presence of all components and ruling out photobleaching of eGFP in the irradiated areas. A detailed analysis of additional micrographs in pseudo-colour with ratiometric changes is shown in the Supplementary Information (Supplementary Figs 14-23 ). This is the first example of controlled 5-InsP 7 10 augmentation inside of a living cell within a few seconds timeframe coupled to a microscopic readout on the single cell level. We posit that this strategy will be useful to understand InsP 7 signalling in more detail as previously possible, as evidenced by the delayed PH-domain translocation observed for the first time in our experiments.
Discussion
This study provides a new strategy to synthesize InsP 7 that enables introduction of caging subunits. The potential utility of TiO 2 microsphere enrichment method was applied to study the in cellulo stability of 5-InsP 7 analogues and their efficient photochemical release in combination with MALDI mass spectrometry. We expect that this combined synthesis, delivery and analytical strategy will find widespread and general application in cell signalling studies as a convenient way to rapidly augment 5-InsP 7 10 with spatiotemporal resolution. Along these lines, it was shown that cytoplasmic release of 5-InsP 7 triggers delayed but complete membrane desorption of the PH-domain of Akt within 15 min. In the human proteome, PH-domains are the 11th most common domain 51 , and the new approach described in this publication will enable a systematic understanding of the effect of inositol-pyrophosphate augmentation on protein localization.
Methods
Experimental data of synthetic compounds. Cellular uptake by flow cytometry. Caged-IP7 9 and oligomer 11 were brought up in pH 7.4 PBS buffer at 1 mM concentrations. HeLa cells were seeded at 40,000 cells per well in a 24-well plate and allowed to adhere overnight. The IP7:co-oligomer complexes were formed at a 1:1 molar ratio by mixing 8 ml of 1 mM oligomer stock with 8 ml of 1 mM caged-IP7 9 stock in 184 ml PBS pH 7.4. For conditions with caged-IP7 9 alone, 8 ml of 1 mM caged-IP7 9 stock was added to 192 ml PBS pH 7.4. The complexes were allowed to incubate for 30 min at room temperature. The Lipofectamine 2000 control was prepared in OptiMEM according to the manufacturer's instructions (0.75 ml Lipofectamine into 62.5 ml. OptiMEM, 8 ml caged-IP7 9 stock into 54.5 ml OptiMEM). The cells were washed with B0.5 ml serum-free DMEM medium, then 400 ml serum-free DMEM was added to wells with untreated cells; 368.75 ml to wells treated with Lipofectamine 2000; 350 ml to treated wells. Then 31.25 ml Lipofectamine:caged-IP7 9 and 50 ml of the caged-IP7:co-oligomer complexes were added to each respective well for a final caged-IP7 9 concentration of 5 mM; all conditions were performed in triplicate. The cells were incubated at 37°C for 3 h. The medium was then removed and the cells were washed with 1.0 ml PBS. About 0.4 ml EDTA trypsin was added, and the cells incubated for 8 min at 37°C. Next, 0.6 ml of serum-containing DMEM medium was added, and the contents of each well were transferred to a 15 ml centrifuge tube and centrifuged (1,200 r.p.m. for 5 min). The cells were collected and re-dispersed in 200 ml PBS, transferred to FACS tubes, and read on a flow cytometry analyser. Results were analysed using FlowJo software. The data presented are the mean fluorescent signals from 10,000 cells analysed.
Fluorescence microscopy. Confocal microscopy was conducted on a CLSM SP5 Mid ultraviolet-visible Leica inverted confocal laser-scanning microscope equipped with a 15 W MaiTai DeepSee twophoton laser (Stanford Cell Sciences Imaging Facility, Award #S10RR02557401 from the National Center for Research Resources). HeLa cells were incubated in serum-free DMEM with 5 mM 9 or 9 þ 11 (equimolar), for 4 or 16 h. After incubation, media was removed and cells washed 3 Â with 1.0 mg ml À 1 heparin (180 U mg À 1 , Aldrich) solution in PBS, then imaged in clear serum-free DMEM. Pictures were recorded with a HCX APO L Â 20/1.00 water immersion objective and photomultiplier tube detector.
eGFP-Akt-PH-domain translocation. Mammalian cells (HeLa Kyoto) were grown up to 50-60% confluence (eight wells Lab-Tek Chamber Slide) in 250 ml DMEM (10% FBS, 10% Pen/Strep, high glucose (4.5 g l À 1 )) at 37°C, 5% CO 2 for 16 h. Cells were then washed with 250 ml PBS followed by a wash with serum-free DMEM (-FBS, -Pen/Step). About 230 ml serum-free DMEM medium were then added to each well.
Transfection of HELA cells with the eGFP Akt-PH-domain for imaging: The transfection mixture was prepared for eight wells. About 200 ng DNA (eGFP-Akt-PH) in 150 ml DMEM (-FBS) were incubated for 10 min at room temperature. Then, 10 ml FuGENE transfecting reagent were added to DNA containing DMEM (-FBS) medium and incubated for 20 min at room temperature. About 20 ml of the transfection mixture were then added to each well. Cells were incubated for 6-8 h at 37°C (5% CO 2 .). After this period, the transfection mixture was removed by washing the cells with 250 ml PBS and DMEM (-FBS). Cells were starved by adding 250 ml DMEM (-FBS) and incubated for 14-16 h at 37°C (5% CO 2 ).
After overnight starvation, the cells were washed with PBS (250 ml) and 230 ml DMEM (-FBS) were added. Afterwards, 20 ml sample mixture (consisting of caged InsP 7 :Co-oligomer (D:G7:7) complexes) were added to each well and distributed equally. The final concentration of the complex was 5 mM for each well. Cells were then incubated at 37°C (5% CO 2 ) for 4 h.
Imaging of Akt-PH translocation. After 4-h incubation with 9 and 11, HeLa cells were washed with 250 ml (2 Â ) imaging buffer (115 mM NaCl, 1.2 mM CaCl 2 , 1.2 mM MgCl 2 , 1.2 mM K 2 HPO 4 , 20 mM HEPES). About 200 ml imaging buffer were added to the wells. Translocation of eGFP-Akt-PH to the membrane was stimulated by adding a mixture of growth factors EGF and IGF (100 ng ml À 1 each). Translocation was monitored over 10 min at 37°C (5% CO 2 ).
Cells that had responded to treatment with the growth factors and that had the PH-domain localized at the membrane were used in the uncaging experiments by confocal laser-scanning microscopy. Non-illuminated neighboring cells were used as controls.
Confocal laser-scanning microscopy. Imaging was performed on an Olympus IX83 confocal laser-scanning microscope at 37°C in a 5% CO 2 high humidity atmosphere (EMBL incubation box). Imaging was performed using an Olympus Plan-APON Â 60 (numerical aperture 1.4, oil) objective. The images were acquired utilizing a Hamamatsu C9100-50 EM CCD camera. Image acquisition was performed via FluoView imaging software, version 4.2. The green channel was imaged using the 488 nm laser line (120 mW cm À 2 ) at 3% laser power and a 525/50 emission mirror. The red channel was imaged using the 559 nm laser (120 mW cm À 2 ) at 2.0% laser power and a 643/50 emission filter. A pulsed 375 nm laser line (10 MHz) was applied for uncaging experiments. For uncaging experiments, circular regions of interest of 4-10 mm diameter were pre-defined. Pre-activation images were captured for five frames (5 s per frame), followed by 30 s of activation within the regions of interest. Recovery images were captured for 35 min at a frame rate of 5 s per frame.
Image analysis. Image analysis was conducted utilizing Fiji open source image analysis software tool 52 . Lookup tables were applied to match the colour within the recorded image with the wavelengths of detected light. For comparability, the lookup tables of pre-and postactivated images were set the same weighting.
